TABLE 1.
Clinical and demographic characteristics of IIMs patients
| Characteristics | Hypertension (n=54) | Non‐hypertension (n=308) | Total (n=362) | |
|---|---|---|---|---|
| Age (n, %) (years) | ||||
| <50 | 16(29.6) | 181(58.8) | 197(54.4) | |
| ≥50 | 38(70.4) | 127(41.2) | 165(45.6) | |
| Gender (n,%) | ||||
| Female | 40(74.1) | 205(66.6) | 245(67.7) | |
| Male | 14(25.9) | 103(33.4) | 117(32.3) | |
| SBP (mean±SD) (mmHg) | 134±16 | 116±14 | 118 ±16 | |
| DBP (mean±SD) (mmHg) | 85±13 | 72±11 | 74±12 | |
| Follow‐up (n,%) (months) | ||||
| <6 | 26(48.1) | 143(46.4) | 169(46.7) | |
| ≥6 | 28(51.9) | 165(53.6) | 193(53.3) | |
| Smoking (n,%) | ||||
| Yes | 1(1.9) | 25(8.1) | 26(7.2) | |
| No | 53(98.2) | 283(91.9) | 336(92.8) | |
| Diabetes mellitus (n,%) | ||||
| Yes | 10(18.5) | 25(8.1) | 35(9.7) | |
| No | 44(81.5) | 283(91.9) | 327(90.3) | |
| Dysphagia (n,%) | ||||
| Yes | 19(35.2) | 141(45.8) | 160(44.2) | |
| No | 35(64.8) | 167(54.2) | 202(55.8) | |
| Myalgia (n,%) | ||||
| Yes | 20(37.0) | 157(51.0) | 177(48.9) | |
| No | 34(63.0) | 151(49.0) | 185(51.1) | |
| Arthralgia (n,%) | ||||
| Yes | 16(29.6) | 130(42.2) | 146(40.3) | |
| No | 38(70.4) | 178(57.8) | 216(59.7) | |
| Rash | ||||
| Yes | 34(63.0) | 213(69.2) | 247(68.2) | |
| No | 20(37.0) | 95(30.8) | 115(31.8) | |
| Lung involvement (n,%) | ||||
| Yes | 15(27.8) | 101(32.8) | 116(32.0) | |
| No | 39(72.2) | 207(67.2) | 246(68.0) | |
| Gottron's sign (n,%) | ||||
| Yes | 13(24.1) | 84(27.2) | 97(26.8) | |
| No | 41(75.9) | 224(72.7) | 265(73.2) | |
| Raynaud's phenomenon (n,%) | ||||
| Yes | 3(5.6) | 31(10.1) | 34(9.4) | |
| No | 51(94.4) | 277(89.9) | 328(90.6) | |
| ESR (n,%) | ||||
| Normal | 44(81.5) | 214(69.5) | 258(71.3) | |
| Above normal | 10(18.5) | 94(30.5) | 104(28.7) | |
| CRP (n,%) | ||||
| Normal | 33(61.1) | 166(53.9) | 199(55.0) | |
| Above normal | 21(38.9) | 142(46.1) | 163(45.0) | |
| TP (n,%) | ||||
| Below normal | 41(75.9) | 212(68.8) | 253(69.9) | |
| Normal | 13(24.1) | 96(31.2) | 109(30.1) | |
| ALB (n,%) | ||||
| Below normal | 21(38.9) | 154(50.0) | 175(48.3)) | |
| Normal | 33(61.1) | 154(50.0) | 187(51.7) | |
| Urea (n,%) | ||||
| Below normal | 2(3.7) | 44(14.3) | 46(12.7) | |
| Normal | 47(87.0) | 243(78.9) | 290(80.1) | |
| Above normal | 5(9.3) | 21(6.8) | 26(7.2) | |
| Scr (n,%) | ||||
| Below normal | 21(38.9) | 162(52.6) | 183(50.6) | |
| Normal | 33(61.1) | 146(47.4) | 179(49.4) | |
| UA (n,%) | ||||
| Below normal | 13(24.1) | 109(35.4) | 122(33.7) | |
| Normal | 40(74.1) | 194(63.0) | 234(64.6) | |
| Above normal | 1(1.9) | 5(1.6) | 6(1.7) | |
| TG (n,%) | ||||
| Normal | 19(35.2) | 163(52.9) | 182(50.3) | |
| Above normal | 35(64.8) | 145(47.1) | 180(49.7) | |
| TC (n,%) | ||||
| Below normal | 3(5.6) | 20(6.5) | 23(6.4) | |
| Normal | 35(64.8) | 243(78.9) | 278(76.8) | |
| Above normal | 16(29.6) | 45(14.6) | 61(16.9) | |
| HDL‐C (n,%) | ||||
| Below normal | 12(77.8) | 80(74.0) | 92(74.6) | |
| Normal | 42(22.2) | 228(74.0) | 270(74.6) | |
| LDL‐C (n,%) | ||||
| Normal | 44(81.5) | 293(95.1) | 337(93.1) | |
| Above normal | 10(18.5) | 15(4.9) | 25(6.9) | |
| ANA (n,%) | ||||
| Positive | 43(79.6) | 202(65.6) | 245(67.7) | |
| Negative | 11(20.4) | 106(34.4) | 117(32.3) | |
| Anti SSA antibody (n,%) | ||||
| Positive | 2(3.7) | 46(14.9) | 48(13.3) | |
| Negative | 52(96.3) | 262(85.1) | 314(86.7) | |
| Anti SSB antibody (n,%) | ||||
| Positive | 0(0.0) | 16(5.2) | 16(4.4) | |
| Negative | 54(100.0) | 292(94.8) | 346(95.6) | |
| Anti‐SCL‐70 antibody (n,%) | ||||
| Positive | 1(1.9) | 4(1.3) | 5(1.4) | |
| Negative | 53(98.1) | 304(98.7) | 357(98.6) | |
| Anti‐Jo1 antibody (n,%) | ||||
| Positive | 3(5.6) | 23(7.5) | 26(7.2) | |
| Negative | 51(94.4) | 285(92.5) | 336(92.8) | |
| Use of GC (n,%) | ||||
| Yes | 25(46.3) | 131(42.5) | 156(43.1) | |
| No | 29(53.7) | 177(57.5) | 206(56.9) | |
| Use of MTX (n,%) | ||||
| Yes | 7(13.0) | 30(9.7) | 37(10.3) | |
| No | 47(87.0) | 278(90.3) | 325(89.8) | |
| Use of CTX (n,%) | ||||
| Yes | 2(3.7) | 7(2.3) | 9(2.5) | |
| No | 52(96.3) | 301(97.7) | 353(97.5) | |
| Use of HCQ (n,%) | ||||
| Yes | 3(5.6) | 20(6.5) | 23(6.4) | |
| No | 51(94.4) | 288(93.5) | 339(93.6) | |
| Use of AZA (n,%) | ||||
| Yes | 1(1.9) | 7(2.3) | 8(2.2) | |
| No | 53(98.1) | 301(97.7) | 354(97.8) | |
| Use of LEF (n,%) | ||||
| Yes | 1(1.9) | 4(1.3) | 5(1.4) | |
| No | 53(98.1) | 304(98.7) | 357(98.6) | |
| Use of TII (n,%) | ||||
| Yes | 1(1.9) | 8(2.6) | 9(2.5) | |
| No | 53(98.1) | 300(97.4) | 353(97.5) | |
| Use of TGP (n,%) | ||||
| Yes | 1(1.9) | 7(2.3) | 8(2.2) | |
| No | 53(98.1) | 301(97.7) | 354(97.8) | |
Abbreviations: ALB, albumin; ANA, antinuclear antibodies; AZA, azathioprine; CRP, C‐relative protein; CTX, cyclophosphamide; DBP, diastolic blood pressure;ESR, erythrocyte sedimentation rate; GC, glucocorticoid; HCQ, hydroxychloroquine; HDL‐C, high‐density lipoprotein‐cholesterol; LDL‐C, low‐density lipoprotein‐cholesterol; LEF, leflunomide; MTX, methotrexate; SBP, systemic blood pressure; Scr, serum creatinine; TC, total cholesterol; TG, triglyceride; TGP, total glucosides of paeony; TII, tripterygium wilfordii; TP, total protein; UA, uric acid.